Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates.

TitleDesign, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates.
Publication TypeJournal Article
Year of Publication2022
AuthorsMiller M, Rossetti T, Ferreira J, Ghanem L, Balbach M, Kaur N, Levin LR, Buck J, Kehr M, Coquille S, van den Heuvel J, Steegborn C, Fushimi M, Finkin-Groner E, Myers RW, Kargman S, Liverton NJ, Huggins DJ, Meinke PT
JournalJ Med Chem
Volume65
Issue22
Pagination15208-15226
Date Published2022 Nov 24
ISSN1520-4804
KeywordsAdenylyl Cyclases, Animals, Contraceptive Agents, Male, Male, Oocytes, Signal Transduction, Sperm Motility
Abstract

Soluble adenylyl cyclase (sAC: ADCY10) is an enzyme involved in intracellular signaling. Inhibition of sAC has potential therapeutic utility in a number of areas. For example, sAC is integral to successful male fertility: sAC activation is required for sperm motility and ability to undergo the acrosome reaction, two processes central to oocyte fertilization. Pharmacologic evaluation of existing sAC inhibitors for utility as on-demand, nonhormonal male contraceptives suggested that both high intrinsic potency, fast on and slow dissociation rates are essential design elements for successful male contraceptive applications. During the course of the medicinal chemistry campaign described here, we identified sAC inhibitors that fulfill these criteria and are suitable for in vivo evaluation of diverse sAC pharmacology.

DOI10.1021/acs.jmedchem.2c01133
Alternate JournalJ Med Chem
PubMed ID36346696
PubMed Central IDPMC9866367
Grant ListP50 HD100549 / HD / NICHD NIH HHS / United States
R01 AG061290 / AG / NIA NIH HHS / United States
R21 EY025810 / EY / NEI NIH HHS / United States